HOME

AQUEOUS PHARMA

BREAKING NEWS: Aqueous Pharma announces new technology to enhance human tear production. This is product code APL-106 and several clinical studies, conducted in Europe, substantiate the efficacy of the active ingredient. This is early stage but if everything falls into place; APL-106 could easily be a "game changer".

AQUEOUS PHARMA

Aqueous Pharma was founded by Joe Echols so the innovative products developed by Dr Frank Holly would be available to the millions of suffering and unsatisfied dry eye patients, worldwide.

Human Tear Film Protects Ocular Surface

NutraTear, Dakrina & Dwelle were launched in 2005 by The Dry Eye Company LLC, for the USA. These 3 artificial tears are known as the "core tears". The Dry Eye Company no longer have the rights to these 3 products, and they were sold to another company. As these core tears are quite unique and highly effective, the new owner of the rights to these tears have plans to market them in the USA (& possibly Canada)sometime during 2011.

	A Development company dedicated to innovative therapy for Dry Eye Syndrome.
	Artificial Tears are the mainstay therapy for Dry Eye Syndrome.
	FreshKote, the newest artificial tear was launched in the USA by FOCUS Labs on May 1, 2006.
	Each product was developed by the esteemed Dr. Frank Holly and are the only artificial tears that are not only tear substitutes, but address the underlying cause of Dry Eye.
	In the process of commercializing FreshKote (code name: APL-105) on a global basis via out-licensing.